In this study just published in the journal Gut Microbes, GanedenBC30 delayed onset of symptoms and caused a quicker recovery from the infection.
Ganeden Biotech's 14th published paper showing the benefits of GanedenBC30 was recently published in the journal Gut Microbes. This paper is a summary of the work conducted by Dr. Leo Fitzpatrick from the Penn State Medical Center. Dr. Fitzpatrick utilized a previously published model to test the effectiveness of GanedenBC30 against Clostridium Difficile, or C. Diff, when given preventatively. In this study, animals taking GanedenBC30 had a delayed onset of symptoms and a quicker recovery from the infection.
Clostridium Difficile, or C. Diff, sickens more than 500,000 people and causes 15,000-20,000 deaths annually(1). Treating C. Diff infections cost more than $3.2 billion per year(2) and results in more than 2.3 million additional days of hospitalization.
A second study looking at the prevention of the high rate of C. Diff reoccurrences has just been completed with, what we believe, are extremely favorable results. We will report on the findings when they become available. For more information, please contact Ganeden Biotech at email@example.com.
About Ganeden Biotech, Inc.
Founded in 1997, Ganeden Biotech is based in Cleveland, Ohio, and is at the forefront of probiotic research and innovative product development with GanedenBC30®, its patented, probiotic ingredient. GanedenBC30 can be found in more than 50 foods, including popular brands like Red Mango frozen yogurt and ice teas, Naked Pizza pizza dough, Heartland Sweeteners Nevella with Probiotics, and R.C. Bigelow's Herb Plus Tea. For more information on the probiotic ingredient, GanedenBC30 and licensing opportunities for food and beverage applications, visit ganedenlabs.com and GanedenBC30.com.